Search

Your search keyword '"Geater, Sarayut L"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Geater, Sarayut L" Remove constraint Author: "Geater, Sarayut L"
26 results on '"Geater, Sarayut L"'

Search Results

1. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

2. PAP Treatment of Obstructive Sleep Apnea-Hypopnea in Hypertensive Disorders of Pregnancy: A Pilot Randomized Proof-of-the-Concept Study

3. Exploring previously used thresholds for computed tomography‐defined low skeletal muscle mass in predicting functional limitations among lung cancer patients.

4. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

5. Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC

7. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

8. Positive Airway Pressure Treatment of Obstructive Sleep Apnea–Hypopnea in Hypertensive Disorders of Pregnancy: A Pilot Randomized Proof-of-Concept Clinical Trial.

10. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

11. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

14. The hidden financial catastrophe of chronic kidney disease under universal coverage and Thai “Peritoneal Dialysis First Policy”

15. Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common EGFR Mutations, After Chemotherapy: a Phase IV Study

17. Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC

18. Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged >=65 Years : Subgroup Analysis of LUX-Lung 3/6: P1.33: Track: Advanced NSCLC

19. P1.33: Afatinib versus chemotherapy for EGFR mutation-positive NSCLC patients aged ≥65 years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC

20. P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6

21. P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6

22. P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6

23. Afatinib in locally advanced/metastatic NSCLC harboring common EGFRmutations, after chemotherapy: a Phase IV study

24. Impact of Calcium Phosphate Product on Acute Kidney Injury and Mortality: A Retrospective Cohort Study.

25. Transthoracic imaging-guided biopsy of lung lesions: evaluation of benign non-specific pathologic diagnoses.

26. Outcome of ultrasound-guided small-bore catheter drainage in exudative pleural effusions.

Catalog

Books, media, physical & digital resources